Irdabisant

DB12900InvestigationalSmall molecule

Irdabisant has been used in trials studying Cognitive Impairment.

Mechanism: Pharmacologically active on Histamine H3 receptor
Curator reviewed
Formula / weight: C₁₈H₂₃N₃O₂ · 313.401 g/mol (avg)
Also known as: CEP-26401

Resolves to

Compound

Structure

InChIKeyXUKROCVZGZNGSI-CQSZACIVSA-NSMILESC[C@@H]1CCCN1CCCOC1=CC=C(C=C1)C1=NNC(=O)C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Irdabisant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.